CAM
NVAX icon

Concorde Asset Management’s Novavax NVAX Stock Holding History

Concorde Asset Management’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,449
Closed -$273K – 229
2020
Q4 		$273K Buy
+2,449
New +$260K 0.15% 111

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Concorde Asset Management's NVAX Position: Q1 2021 in Review

Concorde Asset Management sold out of Novavax (NVAX) in Q1 2021, closing a stake of 2,449 shares — an estimated $273K sold.

Concorde Asset Management first reported a position in NVAX in Q4 2020 and held it in 1 quarter. The position peaked at $273K in Q4 2020. 389 funds tracked by Wall St. Rank hold NVAX as of Q1 2021.

  • Concorde Asset Management reported no remaining Novavax position as of Q1 2021 after selling out during the quarter.
  • Concorde Asset Management sold 2,449 Novavax shares in Q1 2021, an estimated $273K.
  • Concorde Asset Management first reported a position in Novavax in Q4 2020 and held it in 1 quarter.
  • Concorde Asset Management's Novavax position peaked at $273K in Q4 2020.
  • 389 funds tracked by Wall St. Rank held Novavax as of Q1 2021.

Based on Concorde Asset Management's 13F filing for Q1 2021, filed 27 Apr 2021.